Intravenous Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome, and Others), Route of Administration (Intravenous and Subcutaneous), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global intravenous immunoglobulin market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing elderly population, rising prevalence of immunodeficiency disorders, increased acceptance of IVIG therapies, and increased usage of off-label indications.

Intravenous immune globulin (IVIG) is an antibody-based substance that is administered intravenously through a vein. Antibodies are proteins produced by your body to aid in the fight against infection. Because it fits like a lock and key to every foreign object (such as a bit of a virus or bacteria) that gets into your body, each antibody produced by your body is somewhat different. As you are exposed to various pathogenic organisms that your body perceives to be alien, your body produces hundreds of different antibodies over the course of your life. IVIG is generally utilized in two scenarios. If your body does not produce enough antibodies, you may require IVIG. "Humoral immunodeficiency" is the term for this condition. IVIG just adds more antibodies to your system that your body cannot produce on its own. Antibodies assist your body fight off a wide range of illnesses and generally endure for several weeks to months. If you are receiving IVIG for this reason, you must do so on a regular basis.

Another reason you could require IVIG is if your immune system has begun fighting your own body by generating antibodies against your own cells. Destruction of your own blood platelets, known as immune thrombocytopenia, and destruction of your own red blood cells, known as autoimmune hemolytic anemia, are examples of conditions where this occurs. Experts think IVIG stops your immune system from killing your own cells in certain illnesses, such as nerves that regulate your breathing (in Guillain-Barré syndrome) or nerves that govern feeling (for example, in chronic inflammatory demyelinating polyneuropathy). IVIG is injected into a vein (intravenously) over the course of one to four hours. The amount of IVIG you require for each dosage is determined by your weight and the reason you are receiving IVIG.

IVIG is given in lower doses on a regular basis if the goal is to replenish the antibodies your body should be generating. Your doctor will decide how frequently you will require infusions and how long you'll need to keep getting them (this may need to be re-evaluated periodically depending on your diagnosis). IVIG is given in a few hefty doses if the goal is to prevent your immune system from attacking your own body (occasionally a single dose). After one or a few doses, your doctor can generally detect if the IVIG is working. IVIG is available in a variety of brands. They differ in the manner in which they are made. In general, if you will be taking IVIG on a frequent basis, it is preferable to go with the same kind every time to avoid adverse effects.

IVIG is generally administered in a doctor's office or a hospital setting. If adequate arrangements are made, it may be delivered at home in rare situations, although this is not typical. It is critical that you feel at ease getting your IVIG and that you tell your provider if you have any questions or concerns about any personal restrictions you may be experiencing. As IVIG is produced from blood donated by others, some people are concerned about acquiring a disease from it. The chance of contracting a viral infection through IVIG is quite minimal. IVIG has never given anyone HIV (AIDS-causing virus) because the procedures used to purify it kill bacteria, hepatitis viruses, and other harmful organisms. No one can, however, foresee every new illness that may arise. One of the reasons IVIG is only administered when absolutely necessary, and records of the exact IVIG product number are preserved, is because of this.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing geriatric population in the world is expected to boost the market growth during growth during the forecast period.
• Increasing number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations is projected to market growth during forecast period.
• Rising incidence of primary immune deficiency diseases are anticipated to fuel the market growth during the forecast period.
• Growing demand of IVIG treatments owing to most effective and only therapeutic option available are key factors boosting the market growth during the forecast period.
• Sedentary lifestyle habits and increase in the incidence of lifestyle-related illnesses such as obesity and antibody deficiency disorders are estimated to fuel the market growth.
• Stringent government rules for Intravenous globulin products and high risk of side effects projected to hamper the market during the forecast period.
• Increased focus on R&D and technological advancements are anticipated to create lucrative opportunities for the market players.

Scope of the Report

The report on the global intravenous immunoglobulin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Hypogammaglobulinemia segment is expected to account for a key share
Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment is expected to account for a key share of the market during the forecast period owing to increasing incidences of primary immunodeficiency diseases (PID) worldwide. In individuals with lymphoproliferative diseases, it is the most prevalent chronic immunological deficiency (LPDs). According to the CDC, the global incidence rate of hypogammaglobulinemia was about 2 per 100,000 people in 2012, and it is anticipated to grow in the near future. In the near future, the segment is projected to increase due to the rising frequency of immunodeficiency diseases and the widespread use of IVIG treatments.

On the other hand, the chronic inflammatory demyelinating polyneuropathy segment is anticipated to expand at a rapid pace during the forecast period due to related benefits, such as safety, less invasive treatment options, and user-friendly treatment options, are contributing to the industry's growth. It is most commonly observed in diabetic individuals. Immunosuppressive medications, steroids, and plasmapheresis are all used in the treatment of CIPD. IVIG is a safe and effective alternative to these treatments.

On the other hand, the immunodeficiency segment is anticipated to expand at a rapid pace during the forecast period due to the rise in the number of people with primary and acquired immunodeficiency disorders (PID & AID). In order to clear the infections, PID and AID must be treated with IV antibiotics. For the treatment of immunodeficiency disorders, IVIG replacement therapy is the best option. As a result, the company is projected to develop steadily in the future years.

Intravenous administration segment is expected to constitute a key share
Based on intravenous and subcutaneous, the intravenous immunoglobulin market is bifurcated into intravenous and subcutaneous. The intravenous administration segment is expected to constitute a key share of the market during the forecast period due to increasing usage intravenous immunoglobulins in a variety of immunology applications. The primary treatment for immunodeficiency disease is intravenous immunoglobulin (IVIG) injection. Furthermore, the sector is expected to benefit from an increase in the number of intravenous product approvals and clinical trials for novel therapeutic uses. This segment's growth is expected to be aided by rising healthcare spending and increased awareness of autoimmune disorders.

On the other hand, the subcutaneous administration segment is anticipated to expand at a rapid pace during the forecast period due to increase as the use of subcutaneous IGs in the treatment of PIDs becomes more widespread. This is due to the possible benefits of subcutaneous delivery, such as faster response and fewer adverse effects. Key contributing reasons to the segment's growth include increased use and preference for subcutaneous immunoglobulin in home-based self-infusion immunotherapy. The vast product pipeline of IVIGs given subcutaneously is expected to contribute to the segment's continued expansion.

North America is anticipated to dominate
On the basis of regions, the intravenous immunoglobulin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to the rising level of awareness about products used in the treatment of immunodeficiency disorders, as well as doctors' increasing predisposition for these therapies and rising healthcare spending, are all contributing to market expansion. Changing lifestyles and an aging population that is more susceptible to chronic diseases are two reasons that are fueling the expansion of this business. Furthermore, rising PID occurrences are projected to provide future development prospects for this industry. According to the American Autoimmune Related Disease Association Inc. (AARDA), autoimmune disorders affected almost 50 million Americans in 2012, with the number anticipated to rise during the projection period.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increased awareness and potential prospects for adoption of immunoglobulin-based treatments for the treatment of primary immunological deficiencies, as well as a growing elderly population. Emerging countries, rising healthcare spending, and a fast-increasing immunoglobulin market are all driving to the growth of this industry. Furthermore, growing rates of immunological diseases, increased knowledge of intravenous and subcutaneous immunoglobulin treatments, and improved healthcare facilities are all predicting future growth.

Segments

• Hypogammaglobulinemia
• CIPD
• Immunodeficiency diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

• Intravenous
• Subcutaneous

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc.

Competitive Landscape

Key players competing in the intravenous immunoglobulin market includes Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, and BDI Pharma Inc.

The increasing number of FDA approvals has given this business a substantial boost. As a result, a number of local and foreign businesses have begun to engage in the IVIG industry. To obtain a larger part of the market, industry players are using different tactics such as mergers and acquisitions, distribution, and other collaborative arrangements.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares.